文献速递糖尿病肥胖与代谢综合征

妊娠期鱼类及长链n-3多不饱和脂肪酸补充剂摄入与挪威女性后续2型糖尿病风险

Intakes of Fish and Long-Chain n-3 Polyunsaturated Fatty Acid Supplements During Pregnancy and Subsequent Risk of Type 2 Diabetes in a Large Prospective Cohort Study of Norwegian Women.
PubMed 文献 · Diabetes Care · 2021-01-01

该研究基于挪威母婴队列(MoBa)60,831名无糖尿病女性,用食物频率问卷评估妊娠早期鱼类及LCn-3PUFA补充剂摄入,随访7.5年发现683例2型糖尿病。多变量Cox回归显示,能量校正的精瘦鱼摄入每增加25g/1000kcal与2型糖尿病风险降低相关(HR 0.71, 95%CI 0.53-0.95, P=0.022),但仅见于孕前BMI≥25的女性;总鱼、富脂鱼或LCn-3PUFA补充剂摄入无显著关联。

要点

  • 精瘦鱼摄入与超重/肥胖挪威女性2型糖尿病风险降低相关。
  • 富脂鱼或LCn-3PUFA补充剂摄入与2型糖尿病风险无显著关联。
  • 多数参与者二噁英和二噁英样多氯联苯摄入超过EFSA耐受每周摄入量。

核心结论

  • 精瘦鱼摄入与超重或肥胖的挪威女性经药物治疗的2型糖尿病风险降低相关,而富脂鱼或LCn-3PUFA补充剂无此关联。

研究设计与样本

  • 前瞻性队列研究,纳入挪威母婴队列(MoBa)中基线无糖尿病的60,831名女性,通过 validated 255项食物频率问卷评估妊娠前4-5个月 habitual 饮食,随访7.5年(IQR 6.5-8.5)识别经药物处方数据库确认的2型糖尿病。

主要发现

  • 随访期间683名(1.1%)参与者发生2型糖尿病,中位年龄31岁(IQR 27-34)。
  • 能量校正的精瘦鱼摄入每增加25g/1000kcal,2型糖尿病风险降低(HR 0.71, 95%CI 0.53-0.95, P=0.022),但分层分析仅见于孕前BMI≥25 kg/m2的女性。
  • 总鱼、富脂鱼或LCn-3PUFA补充剂摄入与2型糖尿病风险无显著关联。
  • 甲基汞摄入量低,但大多数参与者的二噁英和二噁英样多氯联苯总和摄入(皮克毒性当量/千克体重/周)超过欧洲食品安全局(EFSA)设定的耐受每周摄入量(TWI)。

关键数值与推荐

  • 精瘦鱼摄入每增加25g/1000kcal对应的2型糖尿病风险HR为0.71(95%CI 0.53-0.95, P=0.022)。
  • 大多数参与者的二噁英和二噁英样多氯联苯摄入超过EFSA TWI。

临床怎么用

  • 对于超重或肥胖的育龄女性,妊娠期适量摄入精瘦鱼可能有助于降低后续2型糖尿病风险。
  • 富脂鱼虽未增加2型糖尿病风险,但需关注其二噁英和二噁英样多氯联苯摄入可能超过EFSA TWI的健康隐患。
  • 不建议仅依赖LCn-3PUFA补充剂来预防2型糖尿病。

局限性

  • 研究为观察性设计,不能证明因果关系。
  • 精瘦鱼摄入与2型糖尿病风险的关联仅在孕前BMI≥25 kg/m2的女性中显著,需谨慎外推。
  • 饮食评估基于妊娠早期食物频率问卷,可能存在回忆偏倚和测量误差。
  • 2型糖尿病仅通过药物使用定义,可能漏诊未用药病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate associations between intakes of total fish, lean fish, fatty fish, and long-chain n-3 polyunsaturated fatty acid (LCn-3PUFA) supplements and risk of type 2 diabetes in women after pregnancy. Furthermore, we sought to compare the estimated intakes of methylmercury (MeHg) and sum of dioxins and dioxin-like polychlorinated biphenyls (dl-PCBs) with tolerable weekly intakes (TWI). RESEARCH DESIGN AND METHODS: Women free of diabetes at baseline (n = 60,831) who participated in the population-based Norwegian Mother, Father and Child Cohort Study (MoBa) were prospectively evaluated for incident type 2 diabetes, identified on the basis of medication usage >90 days after delivery, ascertained through the Norwegian Prescription Database. Dietary intake data were obtained with a validated 255-item food-frequency questionnaire (FFQ), which assessed habitual diet during the first 4-5 months of pregnancy. Intakes of MeHg and sum of dioxins and dl-PCBs were derived with use of a contaminant database and the FFQ. RESULTS: Median age was 31 years (interquartile range 27, 34) at time of delivery, and follow-up time was 7.5 years (6.5, 8.5). Type 2 diabetes occurred in 683 (1.1%) participants. Multivariable Cox regression analyses identified lower risk of type 2 diabetes with increasing energy-adjusted lean fish intake (25 g/1,000 kcal: hazard ratio 0.71, 95% CI 0.53-0.95, P = 0.022). However, in stratified analyses, a lower risk was found only in women with prepregnancy BMI ≥25 kg/m2. There were no associations between intake of total fish, fatty fish, or LCn-3PUFA supplements and type 2 diabetes. MeHg intake was low, but the intake of the sum of dioxins and dl-PCBs (picograms of toxic equivalents/kilograms of body weight/week) exceeded the TWI set by the European Food Safety Authority (EFSA) for the majority of participants. CONCLUSIONS: Intake of lean fish, but not fatty fish or LCn-3PUFA supplements, was associated with lower risk of pharmacologically treated type 2 diabetes in Norwegian women who were overweight or obese. Fatty fish, which contain dioxins and dl-PCBs, did not increase the risk of type 2 diabetes, but the exceedance of the EFSA TWI for dioxins and dl-PCBs is a health concern.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Øyen J, Brantsæter AL, Nøstbakken OJ, et al. Intakes of Fish and Long-Chain n-3 Polyunsaturated Fatty Acid Supplements During Pregnancy and Subsequent Risk of Type 2 Diabetes in a Large Prospective Cohort Study of Norwegian Women. Diabetes Care. 2021. PMID: 34407960. doi:10.2337/dc21-0447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。